financial: Access Pharmaceuticals Investor Call Tomorrow, Wednesday April 4th at... -- DALLAS and NEW YORK, April 3, 2012 /PRNewswire/ --

Access Pharmaceuticals Investor Call Tomorrow, Wednesday April 4th at... -- DALLAS and NEW YORK, April 3, 2012 /PRNewswire/ --

"....Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas......"